Serving leading biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving leading biopharmaceutical companies globally:
Generated: October 21, 2017
What is the competitive landscape for JANSSEN PHARMS, and when can generic versions of JANSSEN PHARMS drugs launch?
JANSSEN PHARMS has fifty-six approved drugs.| International Patents: | 781 |
| US Patents: | 37 |
| Tradenames: | 54 |
| Ingredients: | 34 |
| NDAs: | 56 |
Export unavailable in trial.
Subscribe for complete access.
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
canagliflozin | Tablets | 100 mg and 300 mg | INVOKANA | 3/29/2017 |
canagliflozin andmetforminhydrochloride | Tablets | 50 mg/500 mg, 50mg/1000 mg, 150mg/500 mg, and150 mg/1000 mg | INVOKAMET | 3/29/2017 |
rivaroxaban | Tablets | 10 mg, 15 mg, and 20 mg | XARELTO | 7/1/2015 |
itraconazole | Oral Solution | 10 mg/mL | SPORANOX | 5/3/2013 |
levofloxacin | Oral Solution | 25 mg/mL | LEVAQUIN | 7/30/2009 |
norelgestromin and ethinyl estradiol | Transdermal System | 0.15 mg/0.02 mg per 24 hours | ORTHO EVRA | 3/22/2007 |
galantamine hydrobromide | Extended-release Capsules | 16 mg and 24 mg | RAZADYNE ER | 3/11/2006 |
galantamine hydrobromide | Extended-release Capsules | 8 mg | RAZADYNE ER | 3/2/2006 |
almotriptan malate | Tablets | 6.25 mg and 12.5 mg | AXERT | 12/8/2005 |
topiramate | Tablets | 50 mg | TOPAMAX | 9/8/2005 |
topiramate | Capsules | 15 mg and 25 mg | TOPAMAX SPRINKLE | 9/7/2005 |
methylphenidate hydrochloride | Extended-release Tablets | 18 mg*, 27 mg, 36 mg and 54 mg | CONCERTA | 7/19/2005 |
metformin hydrochloride | Extended-release Tablets | 18 mg, 27 mg, 36 mg and 54 mg | CONCERTA | 7/19/2005 |
risperidone | Orally Disintegrating Tablets | 0.25 mg | RISPERDAL | 4/11/2005 |
risperidone | Orally Disintegrating Tablets | 3 mg and 4 mg | RISPERDAL | 3/23/2005 |
galantamine hydrobromide | Tablets | 4 mg, 8 mg and 12 mg | RAZADYNE | 2/28/2005 |
topiramate | Tablets | 25 mg, 100 mg and 200 mg | TOPAMAX | 12/26/2001 |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7,482,330 | Substituted fused heterocyclic C-glycosides | ► Subscribe | |||||||||||||
| 6,809,107 | Neurotrophic pyrrolidines and piperidines, and related compositions and methods | ► Subscribe | |||||||||||||
| 7,511,022 | Substituted indole-O-glucosides | ► Subscribe | |||||||||||||
| 8,822,458 | Substituted oxazolidinones and their use in the field of blood coagulation | ► Subscribe | |||||||||||||
| 8,129,378 | Substituted oxazolidinones and their use in the field of blood coagulation | ► Subscribe | |||||||||||||
| 6,110,503 | Preparation of biodegradable, biocompatible microparticles containing a biologically active agent | ► Subscribe | |||||||||||||
| 8,202,984 | Glucopyranoside compound | ► Subscribe | |||||||||||||
| 6,548,610 | Method and apparatus for reducing static charges during polymerization of olefin polymers | ► Subscribe | |||||||||||||
| 6,905,654 | Method and apparatus for reducing static charges during polymerization of olefin polymers | ► Subscribe | |||||||||||||
| 6,495,164 | Preparation of injectable suspensions having improved injectability | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Canada | 2549025 | ► Subscribe | |||||||||||||
| Serbia | 20060323 | ► Subscribe | |||||||||||||
| China | 1419444 | ► Subscribe | |||||||||||||
| Taiwan | 200510440 | ► Subscribe | |||||||||||||
| African Intellectual Property Organization (OAPI) | 11740 | ► Subscribe | |||||||||||||
| South Korea | 20090086282 | ► Subscribe | |||||||||||||
| Serbia | 20060079 | ► Subscribe | |||||||||||||
| Canada | 2236691 | ► Subscribe | |||||||||||||
| Poland | 330530 | ► Subscribe | |||||||||||||
| New Zealand | 545304 | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C/GB95/028 | United Kingdom | ► Subscribe | PRODUCT NAME: TOPIRAMATE; REGISTERED: UK 0242/0301 19950718 | ||||||||||||
| 00521 | Netherlands | ► Subscribe | PRODUCT NAME: FENTANYL; REG NO/DATE: EU/2/11/127/001 20111006 | ||||||||||||
| C/GB06/022 | United Kingdom | ► Subscribe | PRODUCT NAME: FENTANYL HYDROCHLORIDE; REGISTERED: UK EU/1/05/326/001 20060124 | ||||||||||||
| C/GB12/058 | United Kingdom | ► Subscribe | PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003 | ||||||||||||
| C/GB98/013 | United Kingdom | ► Subscribe | PRODUCT NAME: LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE; REGISTERED: UK 00242/0314 19970923 | ||||||||||||
| 842 | Luxembourg | ► Subscribe | 91842, EXPIRES: 20220512 | ||||||||||||
| C0051 | France | ► Subscribe | PRODUCT NAME: RIVAROXABAN; REGISTRATION NO/DATE: EU/1/08/472/001-008 20080930 | ||||||||||||
| 0140011 00102 | Estonia | ► Subscribe | PRODUCT NAME: KANAGLIFLOSIIN;REG NO/DATE: K(2013)8171 (LOPLIK) 15.11.2013 | ||||||||||||
| /2015 | Austria | ► Subscribe | PRODUCT NAME: ETHINYLESTRADIOL UND EINE KOMBINATION VON LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 136021 20150224; FIRST REGISTRATION: SK 17/0017/15-S 20150211 | ||||||||||||
| 00670 | Netherlands | ► Subscribe | PRODUCT NAME: CANAGLIFLOZINE; REGISTRATION NO/DATE: EU/1/13/884/001-008 20131118 | ||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,980 others who get our Drug Patent Expiration Alerts:
